Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

30 Nov 2023

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant patients. METHODS: We analyzed the TCGA cohort of HNSCC patients in relation to their activation of 26 immune gene expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Head and Neck Cancer Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38031025
DOI: 10.1186/s12943-023-01905-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patientsPMID 38031025Read ↗

TP53 mutation-associated immunosignatures impact on anti-PD-L1 treatment response in head and neck cancer patients.Semantic proximity Read ↗

Molecular profiling in HNSCC patients targets potential responsiveness to ICIsSemantic proximity Read ↗

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell CancerSemantic proximity Read ↗

Pinpointing the decisive role of TP53 mutations in orchestrating immunosuppression in head and neck squamous cell carcinomaSemantic proximity Read ↗

Integrating Immune Multi-Omics and Machine Learning to Improve Prognosis, Immune Landscape, and Sensitivity to First- and Second-Line Treatments for Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.Semantic proximity Read ↗

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

Molecular profiling of head and neck squamous cell carcinoma.Semantic proximity Read ↗

Multimodal genomic markers predict immunotherapy response in the head and neck squamous cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.